Earnings release KRTL 9.30.24

KRTL Holding Group Inc. (OTC: KRTL) Reports Third Quarter 2024 Financial Results and Operational Highlights

Golden, CO – November 14, 2024 – KRTL Holding Group Inc. (OTC: KRTL) is pleased to announce its financial results for the third quarter ended September 30, 2024, along with updates on its strategic advancements.

Key Financial Highlights:

• Revenue: For the three months ended September 30, 2024, the company recorded revenue of $2,603,125, which included non-cash revenue of $2,600,000 from the receipt of securities on August 1, 2024. The market value of these securities dropped to $1,600,000 as of September 30, 2024, resulting in an unrealized loss.
• Net Income (3 Months): $1,179,713, with Basic and Diluted EPS of $0.01.
• Net Income (9 Months): $1,273,807, with Basic EPS of $0.02 and Diluted EPS of $0.01.

The company’s focus remains on strategic positioning and long-term growth as a pharmaceutical company, despite fluctuations in the valuation of received securities. All securities held by the Company are incidental and are only held as a result of in-kind payments and not for purposes of trading or reinvestment.  The Company has not made any open market or private purchases of any of the securities that it holds.

Operational Progress:

KRTL Holding Group Inc. operates through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp., each dedicated to distinct but complementary sectors. KRTL Biotech, Inc. seeks to be a leader in biotechnology innovation, advancing its industry presence through strategic partnerships that enhance its international collaboration efforts. KRTL International Corp. continues to focus on bridging global markets through consulting, trade, and distribution of advanced bio and agri-technologies, promoting sustainable solutions that drive industry growth across borders.

A cornerstone of KRTL Biotech’s mission is addressing U.S. drug shortages by ensuring the reliable supply of essential medications to hospitals, healthcare providers, and patients. This commitment strengthens the national healthcare system’s resilience and enhances patient outcomes across the country.  We have received permission to distribute our first product, and we are seeking additional approvals for other products.

The full quarterly report for the period ending September 30, 2024, is available on OTC Markets.

For more information, please visit our website at www.krtlholding.com or contact us at info@krtlholding.com.

The information contained herein includes forward-looking statements.  These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.  You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.  Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity.  We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.